{"Clinical Trial ID": "NCT00438100", "Intervention": ["INTERVENTION 1:", "- The capecitabine arm", "- Capecitabine (Xeloda): 1600 mg/m2 orally for days 1 to 21 followed by a 7-day wash; repeat it as a course.", "- Capecitabine: 1600 mg/m2 orally for days 1 to 21 followed by a 7-day wash; repeat it as a course.", "INTERVENTION 2:", "S-1 lock", "S-1: 80 mg/m2 orally daily for days 1 to 28, followed by a 14-day wash; repeat this as a course.", "S-1: 80 mg/m2 orally daily for days 1 to 28, followed by a 14-day wash; repeat this as a course."], "Eligibility": ["Incorporation criteria:", "Breast cancer diagnosed by biopsy with metastases in several organs", "(World Health Organization: WHO) 0-2", "The following functions are maintained in the main organs:", "Number of leukocytes: 4,000/mm3 to 12,000/mm3", "Number of neutrophils: > 2000/mm3 or more", "Number of platelets: < 100 000/mm3 or more", "Hemoglobin: > 9.5 g/dL", "Total Bilirubine: > 1.5 mg/dL", "AST(GOT): less than twice a normal higher value in an establishment", "AST(GPT): less than twice a normal higher value in an institution", "BUN: < 25 mg/dL", "\u2022 Creatinine: within a higher normal value in the establishment", "24 hours creatinine clearance: > 50 mL/min (using the Cockcroft-Gault formula)", "Female cr = body weight x (140-age)/(72 x serum creatinine) x 0.85", "Informed written consent will be obtained for patients entering this study.", "- Exclusion criteria:", "Patients with multiple synchronous cancers", "\u2022 Complicated with infection", "\u2022 Fever suspected of infection", "Metastasis in the central nervous system", "A story of ischemic heart disease", "gastrointestinal ulcer active", "Severe nervous disorders", "Potentially pregnant, pregnant or lactating women", "A severe allergy to medicines", "\u2022 Severe bone marrow suppression", "Severe renal disorders", "To be treated with other antineoplastic agents of pyrimidine fluoride (including any combination therapy)", "To be treated with flucytosin", "\u2022 Concluded with the onset of infection that a study physician considers inappropriate for this study"], "Results": ["Performance measures:", "\u00b7 Progression Free Survival", "[Unspecified]", "Delay: The follow-up period will be two years after the last dose.", "Results 1:", "Title of the arm/group: Capecitabine Arm", "Description of the arm/group: Capecitabine (Xeloda): 1600 mg/m2 on oral sale daily for days 1 to 21 followed by 7 days of washing; repeat it as a course.", "- Capecitabine: 1600 mg/m2 orally for days 1 to 21 followed by a 7-day wash; repeat it as a course.", "Total number of participants analysed: 71", "Median (95% confidence interval)", "Unit of measure: years 1.2 (0.76 to 2.04)", "Results 2:", "Title of arm/group: S-1 Arm", "Description of the arm/group: S-1: 80 mg/m2 for oral use every day from day 1 to 28 followed by a 14-day wash; repeat as a course.", "S-1: 80 mg/m2 orally daily for days 1 to 28, followed by a 14-day wash; repeat this as a course.", "Total number of participants analysed: 65", "Median (95% confidence interval)", "Unit of measure: years 1.3 (0.96 to 2.68)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0.71 (0.00 per cent)", "Adverse Events 2:", "Total: 0/65 (0.00 per cent)"]}